
Merrimack Pharmaceuticals announced that they would cut away 22% of their workforce and their CEO, Robert Mulroy, would leave immediately …
MHRA approves Romvimza for tenosynovial giant cell tumour
Panthera opens clinical trial site at Keele University
Santen joins inaugural Global Summit for Eye Health as partner

